Medical Biotechnology MCQs (Set-2)

Difficulty: Easy & Basic

Given a blood sample and a suspected viral infection, which test directly looks for viral RNA?

A RT-qPCR after reverse transcription
B a chromosome karyotype
C a Western blot of host actin only
D an antibody ELISA alone

A sample contains a pathogen antigen, but the goal is to detect the patient’s antibodies against it. Which ELISA format is suitable?

A competitive PCR with no antibody
B indirect ELISA using immobilized antigen and an enzyme-linked secondary antibody
C direct ELISA using only a DNA primer
D sandwich ELISA with two primers

A lab wants to detect a low-abundance protein in serum with high specificity. Which assay layout is often useful?

A sandwich ELISA with capture and detection antibodies
B DNA microarray without a protein probe
C standard PCR with no reverse transcription
D a karyotype

A qPCR test for a target nucleic acid produces a much lower Ct than a comparable sample. Under validated assay conditions, this generally suggests

A no amplification occurred
B the target was a protein
C more starting target nucleic acid
D less starting target nucleic acid

A genetic test detects a variant associated with altered drug metabolism. The relevant field is

A histology
B industrial fermentation
C pharmacogenomics
D micropropagation

A patient-derived T-cell product is collected, engineered, expanded, and returned to that patient. This approach is

A in vivo vaccination only
B autologous ex vivo cell therapy
C allogeneic embryo transfer
D hybridoma selection

An immunoassay has high background signal in every well. Which step is most likely to reduce nonspecific binding?

A skip the incubation step
B improve blocking and washing
C remove the negative control
D increase the target concentration in all samples

A patient has a positive antibody test but a negative pathogen-RNA test. Which interpretation is most careful?

A the sample must be contaminated
B the antibody result proves current infectiousness
C the tests measure different targets and timing or prior exposure may explain the result
D the RNA test always detects every infection

A laboratory must determine whether a mutation is present in a specific gene. Which method can target that region for analysis?

A ELISA for total protein only
B PCR followed by sequencing or a variant-specific assay
C a cell count
D a vaccine challenge

A test developer wants a positive result only when a specific protein is present. Which assay principle is central to ELISA?

A ribosomes reading the antigen
B cell fusion with a myeloma cell
C DNA polymerase copying the protein
D antibody binding to the target coupled to a measurable enzyme signal

Which feature distinguishes RT-qPCR from a simple antibody test?

A it measures only antigen–antibody binding
B it identifies the patient’s entire phenotype
C it counts immune cells under a microscope
D it amplifies and monitors target nucleic acid

A clinician needs to check whether a known fusion transcript is present. Which assay is a direct molecular approach?

A RT-PCR with primers spanning the transcript junction
B flow cytometry without a target antibody
C ELISA against total albumin
D a bacterial culture

Why might a mammalian cell line be chosen over E. coli for a complex therapeutic glycoprotein?

A bacteria cannot replicate plasmids
B mammalian cells remove every contaminant automatically
C E. coli cannot make any recombinant protein
D mammalian cells can provide eukaryotic folding and glycosylation

A patient is treated with CAR-T cells engineered from their own T cells. The engineered receptor helps the cells

A convert into monoclonal antibodies
B produce insulin in the pancreas
C recognize a selected target on diseased cells
D sequence every tumor mutation

A biosensor detects glucose using an enzyme and an electrical readout. In this design, the electrode acts as the

A transducer
B antibody
C gene promoter
D culture medium

A lab compares gene-expression levels across hundreds of known genes in many samples. Which platform is designed for parallel hybridization?

A Western blot
B chromosome banding
C DNA microarray
D single-target ELISA

An NGS panel is ordered to examine many disease-associated genes at once. Its core advantage is

A massively parallel sequencing of many DNA fragments
B measurement of only one protein at a time
C guaranteed interpretation of every variant
D direct editing of each patient’s genome

A genetic variant is classified as uncertain. What should be avoided?

A treating the uncertain result as a confirmed disease-causing variant
B providing appropriate genetic counseling
C reviewing family or functional evidence
D following validated interpretation standards

During gene therapy, cells are modified outside the body and tested before return. Which benefit does this workflow offer?

A it changes germ cells automatically
B it eliminates all immune risks
C some product checks can be done before administration
D it guarantees permanent cure

A viral vector delivers a therapeutic gene but triggers an immune response. Which trade-off is being encountered?

A antibodies become DNA primers
B a vector cannot enter cells
C the gene is always destroyed in the nucleus
D efficient delivery can come with vector-related immunogenicity

For a vaccine antigen produced in yeast, why is purification performed before formulation?

A to make the antigen replicate as a virus
B to convert protein into a chromosome
C to isolate the desired antigen and control impurities
D to eliminate the need for quality control

A positive result is found in a no-template PCR control. What does this suggest?

A the assay is perfectly specific
B reverse transcription worked correctly
C the patient has the target sequence
D contamination of reagents or setup

A clinical lab compares a new test with a validated reference method. What is the main purpose?

A increase the sample’s DNA concentration
B estimate performance such as sensitivity and specificity
C replace informed consent
D make a variant pathogenic

A recombinant antibody binds a tumor-associated surface protein. What is the key first requirement for its intended targeting?

A expression of chlorophyll
B specific recognition of the target epitope
C ability to amplify DNA
D formation of a hybridoma in the patient

A cell-based therapy is expanded before administration. Which measurement helps confirm the cells are alive at release?

A a pollen germination test
B blood pressure measurement
C DNA microarray only
D viability assay